Presented as acceptance for the first Professor Wallhäußer 2026 Award for Innovations in GMP and Pharmaceutical Technology at GMP-PharmaCongress & GMP-PharmaTechnica 2026.

In this presentation Andrew Gravett, of the AstraZeneca Microbiology Team responsible for the implementation of APAS® Independence globally, gives an overview of why they chose the technology, how the technology works, and their approach to validation and rollout.

It also explores regulatory compliance considerations as well as overcoming obstacles that are often faced when implementing new technology into the environmental monitoring workflow.

Presentation: AstraZeneca

Conference: GMP-PharmaCongress & GMP-PharmaTechnica2026

Date: 24 March 2026

Presenter: Principal Scientist, Microbiology,Global Product Development, Pharmaceutical Technology & Development,AstraZeneca